Findings

What do systematic reviews say?

27 questions · 27 findings · 9 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 14.8%GRADE not reported 0 · 0%Very low 8 · 29.6%Low 8 · 29.6%Moderate 5 · 18.5%High 2 · 7.4%

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

Adverse events Â · adults and children with cystic fibrosis

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Inhaled NO vs placebo

Adverse events · people with SCD

1 finding from 1 review

Inhaled nitric oxide for treating pain crises in people with sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Low

Summary of findings: Inhaled antibiotics vs IV antibiotics

Adverse events · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs placebo

Adverse events Â · adults and children with cystic fibrosis

It is very uncertain whether short‐acting inhaled beta‐2 agonists changes adverse events Â compared with placebo (very low certainty).

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 47 participants
Very low

Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol

Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 600 participants
Moderate

Short‐acting inhaled muscarinic antagonists vs placebo

Adverse events Â · adults and children with cystic fibrosis

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 27 participants
Very low

Summary of findings: inhaled antioxidants vs placebo

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 223 participants
Low

Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)

Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Low

Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)

Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
123 participants
Low

Summary of findings ‐ Inhaled mannitol vs dornase alfa

Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF

1 finding from 1 review

Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
231 participants
Very low

Summary of findings: Inhaled antibiotics plus IV antibiotics vs IV antibiotics

Adverse events (moderate) · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

It is very uncertain whether summary of findings: Inhaled antibiotics plus IV antibiotics changes adverse events moderate adverse events experienced during and after… compared with IV antibiotics only (very low certainty).

1 finding from 1 review

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Cycled inhaled tobramycin vs culture‐based TNS

Adverse effects of antibiotics: proportion of participants with one or more serious adverse event · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Cycled inhaled tobramycin (TNS) probably leads to lower adverse effects of antibiotics: proportion of participants with one… compared with culture‐based TNS (moderate certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
OR 0.85
1 study · 304 participants
Moderate

Summary of findings: anti‐pseudomonal antibiotics vs placebo

Adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1014 participants
Very low

Beta‐2 agonists vs placebo

Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

LAMA vs placebo

Adverse events after tiotropium 5.0 µg · adults and children with cystic fibrosis

LAMAs showed no clear difference in adverse events after tiotropium 5.0 µg compared with placebo (high certainty).

1 finding from 1 review

Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
RR 0.96 [0.88, 1.04]
2 studies · 807 participants
High

Psychological interventions vs active comparators

Anxiety (adverse effect, post‐intervention) · adults (aged 16 years and over) with CF

The review found no eligible studies for this question.

1 finding from 1 review

Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Psychological interventions vs active comparators

Treatment‐related adverse events Depression · adults (aged 16 years and over) with CF

The review found no eligible studies for this question.

1 finding from 1 review

Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: tobramycin for inhalation powder vs tobramycin

Adverse events: number of any adverse event reported · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: tobramycin for inhalation powder showed no clear difference in adverse events: number of any adverse event reported compared with tobramycin (moderate certainty).

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
RR 1.07 [1, 1.15]
1 study · 517 participants
Moderate